{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T11:39:27Z","timestamp":1702121967615},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100008530","name":"FEDER","doi-asserted-by":"crossref","award":["RD12\/0017\/006"],"award-info":[{"award-number":["RD12\/0017\/006"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12879-016-1545-8","type":"journal-article","created":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T09:57:14Z","timestamp":1463133434000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure"],"prefix":"10.1186","volume":"16","author":[{"given":"Jose \u00c1ngel","family":"Fern\u00e1ndez-Caballero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Chueca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Dolores","family":"M\u00e9rida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josefa","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Vinuesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,13]]},"reference":[{"issue":"1","key":"1545_CR1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QAI.0b013e31828ace69","volume":"63","author":"JK Rockstroh","year":"2013","unstructured":"Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, et al. Durableefficacy and safety of raltegravir versus efavirenz when combined with tenofovir\/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013;63(1):77\u201385.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4 Suppl 3","key":"1545_CR2","doi-asserted-by":"crossref","first-page":"19749","DOI":"10.7448\/IAS.17.4.19749","volume":"17","author":"A Carganico","year":"2014","unstructured":"Carganico A, Dupke S, Ehret R, Berg T, Baumgarten A, Obermeier M, et al. New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy. J Int AIDS Soc. 2014;17(4 Suppl 3):19749.","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"1545_CR3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.antiviral.2010.09.016","volume":"88","author":"FM Codo\u00f1er","year":"2010","unstructured":"Codo\u00f1er FM, Pou C, Thielen A, Garc\u00eda F, Delgado R, Dalmau D, et al. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. Antiviral Research. 2010;88(3):281\u20136.","journal-title":"Antiviral Research"},{"issue":"5","key":"1545_CR4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/COH.0b013e328356dcb6","volume":"7","author":"JL Blanco","year":"2012","unstructured":"Blanco JL, Martinez-Picado J. HIV Integrase inhibitors in ART-experienced patients. Curr Opin HIV AIDS. 2012;7(5):415\u201321.","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"1545_CR5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.antiviral.2011.03.178","volume":"90","author":"C Garrido","year":"2011","unstructured":"Garrido C, Soriano V, Geretti AM, Zahonero N, Garcia S, Booth C, et al. Resistance associated mutations to dolutegravir (S\/GSK1349572) in HIV-infected patients-Impact of HIV subtypes and prior raltegravir experience. Antiviral Res. 2011;90(3):164\u20137.","journal-title":"Antiviral Res"},{"issue":"4","key":"1545_CR6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1517\/13543784.2012.661713","volume":"21","author":"C Katlama","year":"2012","unstructured":"Katlama C, Murphy R. Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs. 2012;21(4):523\u201330.","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"1545_CR7","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/1060028013513558","volume":"48","author":"RC Rathbun","year":"2014","unstructured":"Rathbun RC, Lockhart SM, Miller MM, Liedtke MD. Dolutegravir, a Second-Generation Integrase Inhibitor for the Treatment of HIV-1 Infection. Ann Pharmacother. 2014;48(3):395\u2013403.","journal-title":"Ann Pharmacother"},{"key":"1545_CR8","unstructured":"Stanford HIV Database Version 7.0. http:\/\/hivdb.stanford.edu\/ . Accessed 05 Dec 2015."},{"issue":"2","key":"1545_CR9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1473-3099(11)70290-0","volume":"12","author":"J Lunzen Van","year":"2012","unstructured":"Van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S\/GSK1349572) in combination therapy in antiretroviral-na\u00efve adults with HIV: planned interim 48\u00a0week results from SPRING-1, a doseranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12(2):111\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"1545_CR10","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","volume":"207","author":"JJ Eron","year":"2013","unstructured":"Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis. 2013;207(5):740\u20138.","journal-title":"J Infect Dis"},{"issue":"3","key":"1545_CR11","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","volume":"210","author":"A Castagna","year":"2014","unstructured":"Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir.and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210(3):354\u201362.","journal-title":"J Infect Dis"},{"issue":"3","key":"1545_CR12","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jcv.2004.11.006","volume":"33","author":"CB Chew","year":"2005","unstructured":"Chew CB, Potter SJ, Wang B, Wang YM, Shaw CO, Dwyer DE, et al. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J Clin Virol. 2005;33(3):206\u201316.","journal-title":"J Clin Virol"},{"issue":"4","key":"1545_CR13","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1086\/596486","volume":"48","author":"A Coovadia","year":"2009","unstructured":"Coovadia A, Hunt G, Abrams EJ, Sherman G, Meyers T, Barry G, et al. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis. 2009;48(4):462\u201372.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1545_CR14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jcv.2010.03.017","volume":"48","author":"IJ MacLeod","year":"2010","unstructured":"MacLeod IJ, Rowley CF, Thior I, Wester C, Makhema J, Essex M, et al. Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART. J Clin Virol. 2010;48(3):162\u20137.","journal-title":"J Clin Virol"},{"issue":"4","key":"1545_CR15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.eimc.2010.12.006","volume":"29","author":"F Garc\u00eda","year":"2011","unstructured":"Garc\u00eda F, \u00c1lvarez M, Bernal C, Chueca N, Guillot V. Laboratory diagnosis of HIV infection, viral tropism and resistance to antiretrovirals. Enferm Infecc Microbiol Clin. 2011;29(4):297\u2013307.","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"19","key":"1545_CR16","doi-asserted-by":"crossref","first-page":"10245","DOI":"10.1128\/JVI.00894-09","volume":"83","author":"R Quercia","year":"2009","unstructured":"Quercia R, Dam E, Perez-Bercoff D, Clavel F. Selective-advantage profile of human immunodeficiency virus tipe 1 Integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J Virol. 2009;83(19):10245\u20139.","journal-title":"J Virol"},{"issue":"21","key":"1545_CR17","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJM199905273402101","volume":"340","author":"L Zhang","year":"1999","unstructured":"Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340(21):1605\u201313.","journal-title":"N Engl J Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-016-1545-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T21:03:00Z","timestamp":1589662980000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-016-1545-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,13]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1545"],"URL":"https:\/\/doi.org\/10.1186\/s12879-016-1545-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,13]]},"article-number":"197"}}